Research of pharmacokinetics of thalidomide in SD rats with inflammatory bowel disease
- Author:
Ya-Gang LI
1
;
Fu-Lin JIANG
1
;
Yi-Ping LI
1
;
Min HUANG
1
;
Guo-Ping ZHONG
1
;
Ya-Gang LI
2
;
Fu-Lin JIANG
2
;
Min HUANG
2
;
Guo-Ping ZHONG
2
Author Information
- Publication Type:Journal Article
- Keywords: absorption; HPLC/MS-MS; inflammatory bowel disease; pharmacokinetics; rats; thalidomide
- From: Chinese Pharmacological Bulletin 2023;39(2):252-257
- CountryChina
- Language:Chinese
- Abstract: Aim To investigate the absorption of thalidomide in inflammatory bowel disease(IBD)SD rats compared with healthy rats to provide a basis for the safety and efficacy of thalidomide in clinical practice. Method The IBD rat model was induced by the 2, 4, 6-trinitrobenzene sulfonic acid, by which the rats were continuously intervened for six days. The general state and disease activity index of the rats were recorded every day. The rats in IBD group after modeling and control group were administered with thalidomide at a dose of 10 mg·kg-1. The blood sample of the rats was collected at different time points. After a comprehensive evaluation of morphological and histopathological results, the samples of rats with IBD were determined by proven high performance liquid chromatography-mass spectrometry,and the pharmacokinetic parameters were calculated and compared with the healthy rats. Results The body weight of rats in IBD group was obviously lower than that in control group and the disease activity index, score of colonic macroscopic morphous and histopathology were obviously higher than those in control group. The success rate of modeling was 62.5%. The pharmacokinetic results showed that the Cmax(P<0.05)and AUC(P<0.01)of the IBD group both increased by 2 to 3 times, but there was no significant difference in t1/2,Tmax,MRT and other parameters. Conclusions The rate and extent of oral thalidomide absorption of rats in the model of inflammatory bowel disease significantly increase compared to those of healthy rats, which may provide new considerations for clinical practice of thalidomide in the treatment of IBD.
